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Abstract
The genomes of cancers deficient in mismatch repair (MMR) contain exceptionally high numbers 
of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers 
with MMR deficiency were sensitive to immune checkpoint blockade with anti-PD-1 antibodies. 
We have expanded this study to now evaluate efficacy of PD-1 blockade in patients with advanced 
MMR-deficient cancers across 12 different tumor types. Objective radiographic responses were 
observed in 53% of patients and complete responses were achieved in 21% of patients. Responses 
were durable with median progression-free and overall survival still not reached. Functional 
analysis in a responding patient demonstrated rapid in vivo expansion of neoantigen-specific T cell 
clones that were reactive to mutant neopeptides found in the tumor. These data support the 
hypothesis that the large proportion of mutant neoantigens in MMR-deficient cancers make them 
sensitive to immune checkpoint blockade, regardless of the cancers’ tissue of origin.
Therapy with immune checkpoint inhibitors has uncovered a subset of tumors that are highly 
responsive to an endogenous adaptive immune response (1). When the interaction between 
the checkpoint ligands and their cognate receptors on the effector cells is blocked, a potent 
and durable anti-tumor response can be observed and on occasion this response can be 
accompanied by severe autoimmunity (2–5). These findings support the notion that many 
cancer patients contain in their immune system the capacity to react selectively to their 
tumors, ostensibly through recognition of tumor-specific antigens.
The molecular determinants that define this subset of tumors is still unclear, however several 
markers, including PD-L1 expression, RNA expression signatures, mutational burden and 
lymphocytic infiltrates have been evaluated in specific tumor types (6–10). Though such 
markers appear to be helpful in predicting response in specific tumor types, none of them 
have been evaluated prospectively as a pan-tumor biomarker. Another potential determinant 
of response is mutation-associated neoantigens (MANAs) that are encoded by cancers (11–
14). As previously described, mismatch-repair deficient cancers are predicted to have a very 
large number of MANAs that might be recognized by the immune system (15–18). This 
prediction led us to conduct a small phase II study, focused on eleven patients with 
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colorectal cancers, in which it was demonstrated that PD-1 blockade was an effective 
treatment for many patients with these tumors (19). Since the initiation of that trial, other 
studies have shown that the number of mutations in MMR-proficient cancers correlates with 
the response to PD-1 blockade, providing further support for a relationship between 
mutation burden and treatment response (20).
The genomes of mismatch repair-deficient tumors all harbor hundreds to thousands of 
somatic mutations, regardless of their cell of origin. We therefore sought to investigate the 
effects of PD-1 blockade (using the anti-PD-1 antibody pembrolizumab) in mismatch-repair 
tumors independent of the tissue of origin. In the current study, we prospectively evaluated 
the efficacy of PD-1 blockade in a range of different subtypes of mismatch repair-deficient 
cancers (Clinical-Trials.gov number, NCT01876511).
Eighty-six consecutive patients were enrolled between September 2013 and September 2016 
(table S1). The data cutoff was December 19, 2016. All patients received at least one prior 
therapy and had evidence of progressive disease prior to enrollment. Twelve different cancer 
types were enrolled in the study (Fig. 1). All enrolled patients had evidence of mismatch 
repair-deficiency as assessed by either polymerase chain reaction or immunohistochemistry. 
For most cases, germline sequencing of MSH2, MSH6, PMS2 and MLH1 was performed to 
determine if the mismatch repair-deficiencies were associated with a germline change in one 
of these genes (i.e., whether the patients had Lynch Syndrome) (table S2). Germline 
sequence changes diagnostic of Lynch syndrome were noted in 32 cases (48%), with MSH2 
being the most commonly mutated gene. In seven additional cases where germ line testing 
was not performed, the patient reported a family history consistent with a diagnosis of Lynch 
syndrome.
The adverse events to treatment were manageable, and similar to those found in other 
clinical studies employing pembrolizumab, as shown in table S3. While 74% of patients 
experienced an adverse effect, most were low grade. Endocrine disorders, mostly 
hypothyroidism, occurred in 21% of patients and was easily managed with thyroid hormone 
replacement.
Seventy-eight patients had disease that could be evaluated by Response Evaluation Criteria 
In Solid Tumors (RECIST) (Table 1). Objective radiographic responses were noted in 53% 
of patients (46 of 86 patients; 95% CI, 42–64%), with 21% (n = 18) achieving a complete 
radiographic response. Disease control (measured as partial response + complete response + 
stable disease) was achieved in 66 (77%) of the 86 patients (95% CI, 66–85%). 
Radiographic responses could be separated into two classes. First, in twelve cases, scans at 
20 weeks showed stable disease, which eventually converted to an objective response 
(measured as tumor size reduction in response to therapy, according to RECIST criteria). 
Second, in eleven additional cases, we observed an initial partial response or stable disease 
at the 20-week scan that later converted to complete responses while treatment was 
continued. The average time to any response was 21 weeks and the average time to complete 
response was 42 weeks (Fig. 1). Of note, the objective response rate was similar between 
colorectal cancer versus other cancer subtypes. Specifically, objective responses were 
observed in 52% (95% CI 36 to 68%) of patients with colorectal cancers and 54% (95% CI 
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39 to 69%) of the patients with cancers originating in other organs (tables S4 and S5). There 
was also no significant difference in the objective response rate between Lynch and non-
Lynch syndrome-associated tumors; 46% (95% CI of 30 to 63%) versus 59% (95% CI of 41 
to 76%), respectively (p = 0.27).
Neither median progression-free survival (PFS) nor median overall survival (OS) has yet 
been reached (median follow-up time of 12.5 months; Fig. 1) and the study is ongoing. 
However the estimates of PFS at 1- and 2-years were 64% and 53%, respectively. The 
estimates of OS at 1- and 2-years were 76% and 64%, respectively, which is markedly 
higher than expected based on the advanced state of disease in this cohort (21). The PFS and 
OS was not significantly different in patients with colorectal cancers as compared to those 
with other cancer types (fig. S1). Neither PFS (HR 1.2; 95% CI of 0.582 to 2.512, p = 0.61) 
or OS (HR 1.71; 95% CI of 0.697 to 4.196; p = 0.24) were influenced by tumors associated 
with Lynch Syndrome.
Eleven patients achieved a complete response and were taken off therapy after two years of 
treatment. No evidence of cancer recurrence has been observed in those patients with a 
median time off therapy of 8.3 months. Seven other patients had residual disease by 
imaging, but pembrolizumab was discontinued after reaching the 2-year milestone or 
because of intolerance to therapy. To date, the average time off therapy for this group was 
7.6 months. As of the data cutoff, none of these patients has shown evidence of progression 
since discontinuation of pembrolizumab.
Twenty patients with measurable radiographic disease underwent percutaneous biopsies 
between 1 month and 5 months after the initiation of therapy. Twelve of these biopsies 
demonstrated no evidence of tumor cells and were shown to have varying degrees of 
inflammation, fibrosis and mucin, consistent with an ongoing immune response (fig. S2). 
The other eight cases showed residual tumor cells. The absence of cancer cells in post-
treatment biopsies was a strong predictor of progression free survival (HR for PFS was 
0.189, 95% CI 0.046 to 0.767, p = 0.012) with median PFS of 25.9 months versus 2.9 
months for biopsies with evidence of residual tumor. While there was no significant 
difference in OS between patients whose biopsies were positive or negative for tumor cells, 
median OS has not yet been reached in patients with negative biopsies (table S6).
Primary clinical resistance to initial therapy with pembrolizumab (as measured by 
progressive radiographic disease on the first study scan) was noted in twelve (14%) patients 
(Table 1). We determined the exomic sequences of tumor and matched normal DNA from 
three of these patients and compared them to the exomes of 15 primary tumors from patients 
that had achieved objective responses to the therapy (table S7). The three therapy-insensitive 
tumors harbored an average of 1,413 non-synonymous mutations, not significantly different 
from the number in patients with objective responses (1,644 non-synonymous mutations; p = 
0.67, Student’s t test). The gene (B2M) encoding β2-microglobulin, a protein required for 
antigen presentation (22), was not mutated in any of the primary tumors from the resistant 
group (table S8).
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Only five cases of acquired resistance were noted, where patients developed progressive 
disease after an initial objective response to pembrolizumab. Three of these cases were 
atypical in that the tumors emerged in occult sites such as the brain (two cases) or bone (one 
case). All three cases were treated with local therapy (radiation or surgery) and patients 
survived and continued treatment with pembrolizumab. However, in accordance with study 
design, these three patients are listed in Fig. 1 as having progressive disease.
We performed exome sequencing of brain metastases biopsies from two patients and 
compared the results with those of their primary tumors (fig. S3 and table S7). In the first 
case, the primary duodenal tumor and brain metastasis shared 397 non-synonymous somatic 
mutations, providing unequivocal evidence that the metastasis was derived from the primary 
duodenal tumor rather than from an independent tumor. Moreover, the metastasis harbored 
1,010 non-synonymous new mutations not present in the primary tumor, while the primary 
tumor harbored 964 mutations not present in the metastasis (table S9). In the second case, 
the primary colorectal tumor and brain metastasis shared 848 non-synonymous somatic 
mutations, similarly providing unequivocal evidence of a genetic relationship between the 
two lesions. The brain metastasis harbored 221 non-synonymous mutations not present in 
the primary colorectal tumor, while the primary tumor harbored 100 mutations not present in 
the metastasis (table S10). Of note, the brain metastases from both these patients contained 
mutations in the B2M gene. In the patient with the duodenal tumor, a truncating mutation 
(L15Ffs*41) in the B2M gene was identified in the metastasis but not in the primary tumor. 
The primary colorectal tumor harbored a truncating mutation in beta-2-microglobulin 
(V69Wfs*34) while the metastasis retained this mutation and acquired a second B2M 
mutation (12L>P; table S7).
We also evaluated the exomes of three primary tumors from patients that originally had 
stable disease by RECIST criteria at 20 weeks, but disease progressed within 8 months of 
initiating therapy. The average mutational burden was 1,647 for this group, similar to those 
of the other patients described above. Interestingly, two of these three tumors harbored 
mutations of B2M (table S7).
We next sought to directly test the hypothesis that checkpoint blockade induces peripheral 
expansion of tumor-specific T cells and that mismatch repair deficient tumors harbor 
functional MANA-specific T cells. Deep sequencing of TCR CDR3 regions (TCRseq) has 
emerged as a valuable technique to evaluate T cell clonal representation in both tumors and 
peripheral blood. We performed TCRseq on tumors from three responding patients (obtained 
from archival surgical resections) and identified intratumoral clones that were selectively 
expanded in the periphery (Fig. 2A). These clones were present at very low frequency (often 
undetectable) in the peripheral blood before pembrolizumab treatment, but many rapidly 
increased after treatment initiation, followed by a contraction that generally occurred before 
radiologic responses were observed. To characterize functional T cell clones’ specific for 
mutant peptides, we obtained peripheral blood from one of the patients (subject 19). We 
tested the patients post-treatment peripheral blood for reactivity against the 15 top candidate 
MANAs as identified via a neoantigen prediction algorithm (specified by the patient’s HLA 
class I alleles – see supplemental materials) with an IFNγ ELISpot assay. Based on either 
spot-forming cells (SFC) or a cytokine activity analysis, T cell responses were observed 
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against 7/15 peptides (Fig. 2, B and C). We next interrogated the expanded lymphocyte 
populations against these 7 peptides with TCRseq. Clonal T cell expansion was noted in 
response to 3/7 peptides (Fig. 2D), with specificity demonstrated by a lack of significant 
expansion in response to any other peptide tested (fig. S4). In the peripheral blood, T cell 
expansion to these 3 mutant peptides resulted in 142 unique TCR sequences, seven of which 
were found in the tumor sample (2 from MANA1, 3 from MANA2 and 2 from MANA4) 
(Fig. 2D). Of note, the mutant peptides that scored positive all resulted from frameshift 
mutations -the type of mutation that is most characteristic of MMR-deficient cancers.
All seven of the MANA-reactive TCRs were detectable in peripheral blood at very low 
frequency (less than 0.02%) before treatment. However, four of the clones rapidly increased 
in frequency in the peripheral blood following anti-PD-1 treatment (Fig. 2E). Similar to 
results from the three patients analyzed above, frequencies of these functionally validated 
MANA-specific T cell clones peaked soon after treatment and corresponded with 
normalization of the systemic tumor marker and predated objective radiographic response by 
several weeks. This peak in T-cell clonal expansion was followed by significant decreases in 
frequency, reminiscent of T cell responses to acute viral infections (Fig. 2E). Because all the 
MANAs were from frameshift mutations, only MANA2 had a similar wild-type counterpart 
(differing in the two carboxy-terminal amino acids). The corresponding wild-type peptide 
bound to HLA with >100 fold lower affinity than the mutant peptide counterpart (Fig. 2F), 
consistent with the mutation conferring enhanced HLA binding.
To estimate the fraction of cancer patients to which the results of this study might be 
applicable, we evaluated 12,019 cancers representing 32 distinct tumor types for MMR-
deficiency using an NGS based approach (Fig. 3). In accordance with a recent independent 
estimate using a different approach (23), we found that >5% of adenocarcinomas of the 
endometrium, stomach, small Intestine, colon and rectum, cervix, prostate bile duct and 
liver, as well as neuroendocrine tumors, non-epithelial ovarian cancers and uterine sarcomas, 
were MMR deficient. Across these 11 tumor types, 8% of stage I to stage III cancers and 4% 
of stage IV cancers were MMR-deficient. This represents roughly 40,000 annual stage I–III 
and 20,000 stage IV diagnoses in the United States alone. Because genetic and 
immunohistochemical tests for MMR-deficiency are already widely available, these results 
tie immunity, cancer genetics, and therapeutics together in a manner that will likely establish 
a new standard-of-care and in the future, testing for MMR-deficiency in patients’ refractory 
to other treatments might be considered in order to identify those who may benefit from 
PD-1 pathway blockade, regardless of tumor type.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Patient survival and clinical response to Pembrolizumab across 12 different tumor types 
with mismatch repair deficiency
(A) Tumor types across 86 patients. (B) Waterfall plot of all radiographic responses across 
12 different tumor types at 20 weeks. Tumor responses were measured at regular intervals 
and values show the best fractional change of the sum of longest diameters (SLD) from the 
baseline measurements of each measurable tumor. (C) Confirmed radiographic objective 
responses at 20 weeks in blue compared to the best radiographic responses in the same 
patients in red. The mean time to the best radiographic response was 28 weeks. (D) 
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Swimmer plot showing survival for each patient with mismatch repair deficient tumors, 
indicating death, progression and time off therapy. (E) Kaplan-Meier estimates of 
progression-free survival and (F) overall patient survival.
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Fig. 2. TCR clonal dynamics and mutation associated neoantigen recognition in patients 
responding to PD-1 blockade
(A) T cell receptor (TCR) sequencing was performed on serial peripheral T cell samples 
obtained before and after PD-1 blockade. Tumor tissue with mismatch repair deficiency was 
obtained from three responding patients. Figures show 15 TCR clones with the highest fold 
change in frequency after treatment (left panels) that was also found in the original tumor 
(right panels). (B) Whole exome sequencing was performed on tumor and matched normal 
tissue from patient 19. Somatic alterations were analyzed using a neo-antigen prediction 
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pipeline to identify putative mutation associated neoantigens (MANAs). Reactivity to 15 
candidate MANAs was tested in a 10 day cultured IFNγ ELISpot assay. Data are shown as 
the mean number of spot forming cells (SFC) per 106 T cells (top) or mean cytokine activity 
(bottom) of triplicate wells +/− SD. (C) Seven candidate MANAs were selected for TCR 
analysis based on ELISpot reactivity (D) MANA-specific T cell responses were identified 
against 3/7 candidate MANAs (MANA1, MANA2 and MANA4) after a 10-day in vitro 
stimulation (left panels). MANA specific clones were identified by significant expansion in 
response to the relevant peptide and no significant expansion in response to any other 
peptide tested (fig. S3). Data are shown as the fold change in TCR clone frequency 
compared to the frequency of that clone after identical culture without peptide. These T cell 
clones were also found in the original tumor biopsy (right panels). (E) Frequency of MANA-
specific clones, carcinoembryonic antigen (CEA) and radiographic response in the tumor 
[from (D)] were tracked in the peripheral blood before treatment, and at various times after 
pembrolizomab treatment. Time is shown in weeks after first pembrolizumab dose. (F) In 
vitro binding and stability assays demonstrate the affinity kinetics of each relevant MANA 
and the corresponding WT peptide (when applicable) for their restricting HLA I allele. The 
A*02:01-restricted Influenza M GILGFVTL epitope was used as a negative control for each 
assay and known HLA-matched epitopes were used as positive controls when available. 
Data are shown as counts per second with increasing peptide concentration for binding 
assays (top panel) or counts per minute over time for stability assays (bottom panel). Data 
points indicate the mean of two independent experiments +/− SD. *p < 0.05, **p < 0.01, 
***p < 0.001.
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Fig. 3. Mismatch repair deficiency across 12,019 tumors
Proportion of tumors deficient in mismatch repair in each cancer subtype, expressed as a 
percentage. Mismatch repair deficient tumors were identified in 24 out of 32 tumor subtypes 
tested, more often in early stage (defined as stage < IV) disease.
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Table 1
Summary of therapeutic response to pembrolizumab (anti-PD-1) treatment
Radiographic responses, progression-free survival (PFS) and overall survival (OS) estimates were measured 
using the Response Evaluation Criteria In Solid Tumors (RECIST v1.1) guidelines. Patients were considered 
not evaluable if they did not undergo a 12-week scan due to clinical progression. The rate of disease control 
was defined as the percentage of patients who had a complete response, partial response, or stable disease for 
12 weeks or more. NR, not reached.
Type of response Patients (n = 86)
Complete response 18 (21%)
Partial response 28 (33%)
Stable disease 20 (23%)
Progressive disease 12 (14%)
Not evaluable 8 (9%)
Objective response rate
95% CI
53%
42% to 64%
Disease control rate
95% CI
77%
66% to 85%
Median progression-free survival time
95% CI
NR
14.8 months to NR
2-year progression-free survival rate
95% CI
53%
42% to 68%
Median overall survival time
95% CI
NR
NR to NR
2-year overall survival rate
95% CI
64%
53% to 78%
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